p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer.

doi:10.12688/f1000research.108628.2

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer.

F1000Research - 1 Jan 2022

Halim Freda, Azhar Yohana, Suwarman Suwarman, Hernowo Bethy

Abstract excerpt

Endocrine therapy resistance in Luminal Breast Cancer is a significant issue to be tackled, but currently, no specific biomarker could be used to anticipate this event. p53 mutation is widely known as one of Breast Cancer's most prominent genetic alterations. Its mutation could generate various effects in Estrogen Receptor and Progesterone Receptor molecular works, tangled in events leading to the aggravation of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Breast Neoplasms
Share to Mutation
Share to Receptors, Estrogen

Source

Open in PubMed Open full text

Identifiers

PMID: 36519010
DOI: 10.12688/f1000research.108628.2
PMCID: PMC9718986.2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Receptors, Progesterone

Share to Tumor Suppressor Protein p53